Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry-Reference-Cited by-同舟云学术

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

Published:2009-07 Issue:7 Volume:60 Page:1884-1894
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Tubach F.,Salmon D.,Ravaud P.,Allanore Y.,Goupille P.,Bréban M.,Pallot-Prades B.,Pouplin S.,Sacchi A.,Chichemanian R. M.,Bretagne S.,Emilie D.,Lemann M.,Lorthololary O.,Mariette X.,

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.24632/fullpdf

Reference29 articles.

1. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden;Askling;Arthritis Rheum,2005

2. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register;Dixon;Arthritis Rheum,2006

3. Infections and anti-tumor necrosis factor α therapy;Ellerin;Arthritis Rheum,2003

4. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report;Gomez-Reino;Arthritis Rheum,2003

5. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent;Keane;N Engl J Med,2001

Cited by 544 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol;BMJ Open;2024-09

2. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review;Clinical Microbiology and Infection;2024-08

3. Biologics for Psoriasis;Dermatologic Clinics;2024-07

4. Tuberculosis and Immune Reconstitution Inflammatory Syndrome in Patients With Inflammatory Bowel Disease and Anti-TNFα Treatment: Insights From a French Multicenter Study and Systematic Literature Review With Emphasis on Paradoxical Anti-TNFα Resumption;Open Forum Infectious Diseases;2024-06-17

5. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy;Journal of Infection and Public Health;2024-06